




FIG. 1




FIG. 2

300




FIG. 3




FIG. 4




FIG. 5




FIG. 6

	Risk Score
0 Med	0
1-5 Meds	1
6-10 Meds	3
11-15 Meds	6
16-21 Meds	9
22+ Meds	12
Anticholinergic Burden score	Actual value of ACB score (i.e. ACB score = 6 then Risk score = 6) MAXIMUM Score = 6
Sedative Burden Score	Actual value of SB score (i.e. SB score = 3 then Risk score = 3) MAXIMUM Score = 5
Competitive inhibition: INHIBITOR and SUBSTRATE	5 MAXIMUM SCORE = 5
Competitive inhibition: INDUCER and SUBSTRATE	5 MAXIMUM SCORE = 5
Competitive inhibition: 3 SUBSTRATES SAME ISOENZYME	3 MAXIMUM SCORE = 6
Competitive inhibition: 2 SUBSTRATES SAME ISOENZYME	2 MAXIMUM SCORE = 4
LQTS SCORE	0-4 = 0 4.5-7.5 = 2 8-11 = 5 11.5-15 = 7 15+ = 10
Pharmacogenomics CYP2D6 substrates	5 MAXIMUM SCORE = 5
Pharmacogenomics CYP2C19 substrates	3 MAXIMUM SCORE = 3
Pharmacogenomics CYP2C9 substrates	3 MAXIMUM SCORE = 3
Pharmacogenomics CYP3A4 substrates	2 MAXIMUM SCORE = 1
RENAL FUNCTION (TBD)	MAXIMUM SCORE 10
TOTAL SCORE	Add all individual Risk Score values (Maximum score is 75)

FIG. 7

Risk Factor	Percentiles at high risk	Number of Patients
Total Risk Score	10.14%	30633
Medication Count	13.91%	42045
Cognitive Impairment	9.11%	27521
Sedation	11.78%	35610
Heart-Rhythm Impairment	2.60%	7847
Competitive Inhibition	11.19%	33813

FIG. 8

Individualized Risk Score Visualization

RISK SCORE 19/50




FIG. 9

PATIENT INFORMATION

eMTM Date: 5/6/2016

First Name:

Last Name:

Gender: Male

Estimated CrCl: UNKNOWN

MRPs = medication-related problems

DOB: 09/15/1948 (67 years)

MRPs: Not Specified

Prescriber Location: TFP

Race: White or Caucasian

Adherence Score: 1=Medium Adherence

EXECUTIVE SUMMARY OF RECOMMENDATIONS: [PLEASE REFER TO PAGE 5 FOR FULL RATIONALE]

1. Decrease dose or discontinue Canagliflozin due to renal impairment.

2. Consider discontinuing proton pump inhibitor therapy (via step down therapy) or, at minimum, decreasing the dose of pantoprazole.

3. Consider replacing Metoprolol with Bisoprolol as an alternative due to a (a) drug-gene interaction, and (b) drug-drug interaction.

GENETIC RESULTS SNAPSHOT

ATM CYP4F2

CYP2C19 SLC01B1

CYP2C9 TPMT

CYP2D6 VCORC1

CYP3A4 CYP3A5

ApoE

Thrombosis Profile:

F2 F5 MTHFR (A>C) MTHFR (C>T)

PRE-INTERVENTION

Total Meds: 16

Chronic Meds: 16

ACB Score: 2

SB Score: 3

Renal Function: UNKNOWN

LQTS Score: 0

Competitive Inhibition: 7

Total Risk Score: 21

IF ALL RECOMMENDATIONS ACCEPTED

14

14

1

2

UNKNOWN

0

3

12

Low Risk

High Risk

No variant

1 variant

≥1 [decreased] variants

≥1 [increased] variants

Prescriber Signature:

FIG. 10

10/17




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17